Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:12:12.639Z.
Calculation as of: 2026-10-06T21:12:12.639Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $44.72M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $44.71M | 5.75 | 15.10 | 15.10 | 15.10 |
| DarioHealth Corp. (DRIO)vs › | $44.02M | 8.72 | 6.98 | 6.98 | 6.98 |
| Celularity Inc. (CELU)vs › | $45.73M | N/A | 11.46 | 11.53 | 11.53 |
| CVRx, Inc. (CVRX)vs › | $42.99M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.83M | N/A | N/A | N/A | N/A |
| Instil Bio, Inc. (TIL)vs › | $46.69M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $42.72M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $42.26M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $41.95M | N/A | 7.83 | 14.59 | 14.59 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.92
Forward EPS (Est.)
$-0.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
